Current and Emerging Treatment Options in AML
Symposium
Symposium

Current and Emerging Treatment Options in AML

Focus on Novel, Targeted Agents

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. This activity may contain information on products outside the approved indications where you practice.

Meeting Overview

This 1.5-hour live symposium will provide expert insight into the evolving treatment landscape for patients with acute myeloid leukemia (AML). Discussions will include current and emerging treatment options with a focus on targeted therapy for newly diagnosed as well as for relapsed/refractory disease.

prIME, a Medscape Oncology Company satellite symposium held at the 24th Congress of the European Hematology Association

Date and Location

Thursday, 13 June 2019
12:30 – 14:00

Room: Forum Hall
RAI Amsterdam
Europaplein 24
Amsterdam, the Netherlands

Date/Time

Date/Time

Thursday, 13 June 2019
12:30 – 14:00

Location

Location

Amsterdam, the Netherlands

IME

IME

12:30 Welcome and introduction
Nigel Russell, MD
12:35 Hematology guru: How much do you know about current and emerging treatments for AML?
Nigel Russell, MD
12:40 Current and emerging treatment options for first-line treatment of AML
Giovanni Martinelli, MD, PhD
13:10 Q & A
13:15 Current and emerging treatment options for relapsed/refractory AML
Jorge Cortes, MD
13:45 Q & A
13:50 Have you increased your “guru” status?
Nigel Russell, MD
13:55 Conclusions
Nigel Russell, MD
14:00 Adjourn

Faculty

    Chair

  • Nigel Russell, MDNottingham University Hospitals NHS Trust
    Nottingham, United Kingdom
  • Faculty

  • Jorge Cortes, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Giovanni Martinelli, MD, PhDUniversity of Bologna
    Bologna, Italy

This educational activity is designed for medical oncologists, hematologists, and other healthcare providers involved in the management of patients with AML.

After successful completion of this activity, participants should be able to:

  • Develop optimized treatment strategies for AML using current standards of care
  • Assess new/emerging treatment approaches being explored as treatment options for AML

This educational activity is supported by Agios Pharmaceuticals and Helsinn Healthcare SA.

Independent Medical Education (IME)

This IME activity is organized by prIME, a Medscape Oncology Company. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME, a Medscape Oncology Company.

Sunshine Act/EFPIA

prIME, a Medscape Oncology Company complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME, a Medscape Oncology Company assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of IME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME, a Medscape Oncology Company for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME, a Medscape Oncology Company is committed to providing its learners with high-quality IME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.